Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
Authors
Keywords
-
Journal
LUNG
Volume 201, Issue 3, Pages 255-266
Publisher
Springer Science and Business Media LLC
Online
2023-06-01
DOI
10.1007/s00408-023-00621-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
- (2022) Stefan Klein et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
- (2022) Christian Friedrich et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
- (2022) Lorcan P McGarvey et al. LANCET
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
- (2022) Lorcan McGarvey et al. LUNG
- Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
- (2021) Alyn Morice et al. EUROPEAN RESPIRATORY JOURNAL
- Performance of a digital signal processing algorithm for the accurate quantification of cough frequency
- (2021) Jaclyn A. Smith et al. EUROPEAN RESPIRATORY JOURNAL
- Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough
- (2021) Akio Niimi et al. EUROPEAN RESPIRATORY JOURNAL
- Chronic cough: new insights and future prospects
- (2021) Alyn Morice et al. European Respiratory Review
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
- (2020) Jaclyn A Smith et al. Lancet Respiratory Medicine
- Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough
- (2020) Stuart Mazzone et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration
- (2019) Denis Garceau et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
- (2019) Alyn H. Morice et al. EUROPEAN RESPIRATORY JOURNAL
- The global epidemiology of chronic cough in adults: a systematic review and meta-analysis
- (2015) Woo-Jung Song et al. EUROPEAN RESPIRATORY JOURNAL
- A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response
- (2014) A. H. Morice et al. EUROPEAN RESPIRATORY JOURNAL
- Quality of life in patients with chronic cough
- (2010) Emma C. Young et al. Therapeutic Advances in Respiratory Disease
- P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus
- (2008) Kevin Kwong et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started